Results 211 to 220 of about 1,127,554 (354)

Skeletal Muscle Loss During Neoadjuvant Chemotherapy for Breast Cancer: Diabetes as an Independent Predictor. [PDF]

Eur J Breast Health
Sürmeli ZG, Aslan A, Gado M, Aljowder S, Sajid M, Liaqat S, Alkhalfan N, Abduljawad H, Avcı T, Kula M.   +9 more
europepmc   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, EarlyView.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source

Locally advanced breast cancer is the number of dissected nodes after neoadjuvant chemotherapy important? [PDF]

Ecancermedicalscience
Del Valle Peña Colmenares J, Villegas Rodríguez WJ, Zaky OB, Martínez CE, Angulo Herrera DJ.   +4 more
europepmc   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

International Journal of Cancer, EarlyView.
What's New? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey, Heike Löser, Tillmann Bedau, Wolfgang Schröder, Christiane J. Bruns, Thomas Zander, Max Krämer, Reinhard Büttner, Alexander Quaas   +8 more
wiley   +1 more source

Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study. [PDF]

Cancers (Basel)
Pitout A, Mazeaud C, Blondeau A, Salleron J, Massard V, Lambert A.   +5 more
europepmc   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source

MRI-based intratumoral and peritumoral radiomics predicting neoadjuvant chemotherapy response in osteosarcoma. [PDF]

Front Oncol
Zheng T, Bai Y, Ren D, Sui Q, Qian Z, Xu C, Wang L, Zhao K, Fang Y, Li T.   +9 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer. [PDF]

Breast Cancer Res Treat
de Moura Leite L, de Almeida GR, Tavares MC, Cesca MG, Campos FAB, de Oliveira FA, Dornellas DMS, Saldanha EF, Guimarães PT, de Arruda DDS, de Held MFSD, Viana RL, Moura FGR, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Sanches SM, de Lima VCC.   +19 more
europepmc   +1 more source